

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

*This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for the securities of the Company.*



## **Boill Healthcare Holdings Limited**

**保集健康控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock code: 1246)**

### **CLARIFICATION ANNOUNCEMENT**

- (1) PROPOSED SHARE CONSOLIDATION;**
- (2) PROPOSED CHANGE IN BOARD LOT SIZE;**
- (3) MAJOR AND CONNECTED TRANSACTION INVOLVING THE  
ISSUE OF CONSIDERATION SHARES UNDER SPECIFIC MANDATE;**
- AND**
- (4) APPLICATION FOR WHITEWASH WAIVER**

Reference is made to the circular of Boill Healthcare Holdings Limited (the “**Company**”) dated 25 August 2020 (the “**Circular**”) in relation to, among other matters, the proposed Share Consolidation, the Change in Board Lot Size, the Acquisition and the Whitewash Waiver. Unless otherwise stated, capitalised terms used in this announcement shall bear the same meanings as defined in the Circular.

Due to an inadvertent error, certain information was not disclosed in the Circular. The Company would like to provide further disclosure of certain information in accordance with Schedule II and Schedule VI of the Takeovers Code to the Shareholders.

### **IMPLICATIONS OF THE ACQUISITION UNDER THE TAKEOVERS CODE AND APPLICATION FOR THE WHITEWASH WAIVER**

Under the section headed “Implications of the Acquisition under the Takeovers Code and application for the Whitewash Waiver” of the Circular on page 29, upon the allotment and issue of the Consideration Shares to the Vendor, the aggregate shareholding of the Vendor and parties acting concert with it will exceed 50%. The Vendor and parties acting in concert with it may increase their shareholding in the Company without incurring any further obligation under Rule 26 of the Takeovers Code to make a general offer.

## **ADDITIONAL DISCLOSURE PURSUANT TO THE TAKEOVERS CODE**

Under the paragraph headed “Additional disclosure pursuant to the Takeovers Code” of the Circular on page VI-6, the Company confirms that as at the Latest Practicable Date, none of the subsidiaries of the Company, pension funds of the Company or of any member of the Group or by a person who is presumed to be acting in concert with the Company by virtue of class (5) of the definition of “acting in concert” or who was an associate of the Company by virtue of class (2) of the definition of “associate” under the Takeovers Code had owned or controlled, or had dealt for value in, any Shares or any securities, convertible securities, warrants, options or derivatives in respect of any Shares or securities of the Company during the Relevant Period.

Save as disclosed above, all information set out in the Circular remains unchanged.

By Order of the Board  
**Boill Healthcare Holdings Limited**  
**Dai Dong Xing**  
*Executive Director and Chairman*

Hong Kong, 7 September 2020

*As at the date of this announcement, the Company has (i) two executive Directors, namely Mr. Dai Dong Xing and Mr. Zhang Sheng Hai; (ii) one non-executive Director, namely Mr. Chui Kwong Kau; and (iii) three independent non-executive Directors, namely Mr. Chan Chi Keung Billy, Mr. Xu Liang Wei and Mr. Wang Zhe.*

*The Directors jointly and severally accept full responsibility for the accuracy of the information contained in this announcement and confirm, having made all reasonable inquiries, that to the best of their knowledge, opinions expressed in this announcement have been arrived at after due and careful consideration and there are no other facts not contained in this announcement, the omission of which would make any statement in this announcement misleading.*